Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

SA Transcripts 162.33K Followers Follow Mirum Pharmaceuticals, Inc. ( MIRM ) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta September 28, 2026 8:30 AM EDT Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Nancy Shulman - Executive Vice President of Clinical Peter Radovich - COO & President Eric Bjerkholt - Chief Financial Officer Rob Myers - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Kalpit Patel - Wolfe Research, LLC Joseph Thome - TD Cowen, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Avraham Novick - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Presentation Operator Good morning, and welcome to the Mirum Pharmaceuticals Business Update Call. My name is Hillary, and I will be your operator today. [Operator Instructions] I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Andrew, please go ahead. Andrew McKibben Senior Vice President, Strategic Finance & Investor Relations Thank you, Hillary, and good morning, everyone. I'd like to welcome you to Mirum's conference call to discuss top line results from the Phase III portion of the AZURE-1 study of Brelovitug in chronic hepatitis delta, along with 48-week data from the Phase IIb portion of the study. For our prepared remarks, I'm joined today by our Chief Executive Officer, Chris Peetz; our Executive Vice President of Clinical Development, Nancy Shulman; and Peter Radovich, our President and